Top

Current Urology Reports

Published in:

01-07-2017 | Prostate Cancer (S Prasad, Section Editor)

The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update

Authors: Greg Kauffmann, Stanley L. Liauw

Published in: Current Urology Reports | Issue 7/2017

Abstract

Purpose of Review

Androgen deprivation therapy (ADT) is an important adjunctive therapy to external beam radiation therapy (RT) for the definitive management of prostate cancer. The role of ADT is well-established for locally advanced or high-risk disease in conjunction with standard doses of RT, but less defined for intermediate-risk disease or with dose-escalated RT. The goal of this review is to summarize evidence evaluating the combination of ADT/RT, focusing on recent trials and current controversies as they pertain to the practicing clinician.

Recent Findings

The benefit of ADT on biochemical control is maintained with dose-escalated RT according to recently reported phase III studies. Furthermore, there is now prospective, randomized evidence to support the addition of ADT to RT in the post-prostatectomy setting.

Summary

ADT continues to play an important role for prostate cancer patients receiving dose-escalated RT. Future research is needed to identify subgroups most likely to benefit from this combination.

Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3(11):1245–53. doi:10.1158/2159-8290.CD-13-0172.CrossRefPubMedPubMedCentral

Milosevic M, Chung P, Parker C, Bristow R, Toi A, Panzarella T, et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res. 2007;67(13):6022–5. doi:10.1158/0008-5472.CAN-07-0561.CrossRefPubMed

Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365(2):107–18. doi:10.1056/NEJMoa1012348.CrossRefPubMed

Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002;20(15):3199–205. doi:10.1200/JCO.2002.01.086.CrossRefPubMed

Witjes WP, Schulman CC, Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European study group on neoadjuvant treatment of prostate cancer. Urology. 1997;49(3A Suppl):65–9.CrossRefPubMed

Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron depot neoadjuvant prostate cancer study group. J Urol. 1995;154(2 Pt 1):424–8.CrossRefPubMed

Dalkin BL, Ahmann FR, Nagle R, Johnson CS. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol. 1996;155(4):1357–60.CrossRefPubMed

Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol. 1996;156(3):873–7.CrossRefPubMed

Van Poppel H, De Ridder D, Elgamal AA, Van de Voorde W, Werbrouck P, Ackaert K, et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol. 1995;154(2 Pt 1):429–34.CrossRefPubMed

10.

Kalina JL, Neilson DS, Comber AP, Rauw JM, Alexander AS, Vergidis J, et al. Immune modulation by androgen deprivation and radiation therapy: implications for prostate cancer immunotherapy. Cancers (Basel). 2017;9(2):13. doi:10.3390/cancers9020013.CrossRef

11.

Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–6.CrossRefPubMed

12.

Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–73. doi:10.1016/S1470-2045(10)70223-0.CrossRefPubMed

13.

Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, et al. Updated results of the phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49(4):937–46.CrossRefPubMed

14.

Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61(5):1285–90. doi:10.1016/j.ijrobp.2004.08.047.CrossRefPubMed

15.

Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50(5):1243–52.CrossRefPubMed

16.

Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26(4):585–91. doi:10.1200/JCO.2007.13.9881.CrossRefPubMed

17.

Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the trans-Tasman radiation oncology group 96.01 randomised controlled trial. Lancet Oncol. 2005;6(11):841–50. doi:10.1016/S1470-2045(05)70348-X.CrossRefPubMed

18.

Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12(5):451–9. doi:10.1016/S1470-2045(11)70063-8.CrossRefPubMed

19.

D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292(7):821–7. doi:10.1001/jama.292.7.821.CrossRefPubMed

20.

D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289–95. doi:10.1001/jama.299.3.289.PubMed

21.

D'Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2015;314(12):1291–3. doi:10.1001/jama.2015.8577.CrossRefPubMed

22.

• Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol. 2016;34(15):1748–56. doi:10.1200/JCO.2015.64.8055. One of the first prospective, randomized trials to demonstrated improved biochemical outcomes with the addition of ADT to dose-escalated RT. CrossRefPubMed

23.

Nabid A, Carrier N, Vigneault E, Souhami L, Lemaire C, Brassard MA, Bahoric B, Archambault R, Vincent F, Nguyen TV. Radiation therapy with or without short-term androgen deprivation therapy in intermediate-risk prostate cancer: results of a phase 3 trial. Int J Radiat Oncol Biol Phys. 2016;94(1):4.CrossRef

24.

BM Dubray, J Salleron, SG Guerif, E Le Prise, A Reynaud-Bougnoux, J-M Hannoun-Levi, TD Nguyen, C Hennequin, J Cretin, M Fayolle-Campana, J-L Lagrange, J-M Bachaud, D Azria, A Grangirard, P Pommier, J-M Simon, M Habibian, P Bey, V Beckendorf. Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial (EU-20503/NCT00104741). J Clin Oncol. 2016;34(suppl; abstr 5021).

25.

•• Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417–28. doi:10.1056/NEJMoa1607529. This phase III trial demonstrated improved long-term outcomes with addition of bicalutamide to post-prostatectomy RT. CrossRefPubMed

26.

• Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17(6):747–56. doi:10.1016/S1470-2045(16)00111-X. One of the first prospective randomized trials to demonstrate improved biochemical outcomes with the addition of ADT to salvage RT. CrossRefPubMed

27.

Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004;171(3):1137–40. doi:10.1097/01.ju.0000112979.97941.7f.CrossRefPubMed

28.

See WA, Tyrrell CJ, Group CEPCT. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol. 2006;132(Suppl 1):S7–16. doi:10.1007/s00432-006-0132-6.CrossRefPubMed

29.

Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(13):1990–6. doi:10.1200/JCO.2005.05.2530.CrossRefPubMed

30.

Kuban DA, Tucker SL. Dong L, Starkschall G, Huang EH, Cheung MR et al. long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74. doi:10.1016/j.ijrobp.2007.06.054.CrossRefPubMed

31.

Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010;28(7):1106–11. doi:10.1200/JCO.2009.25.8475.CrossRefPubMedPubMedCentral

32.

Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475–87. doi:10.1016/S1470-2045(07)70143-2.CrossRefPubMed

33.

Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056–63. doi:10.1016/j.ijrobp.2010.03.049.CrossRefPubMed

34.

Michalski JM, Moughan J, Purdy JA, et al. Initial results of a phase 3 randomized study of high dose 3DCRT/IMRT versus standard dose 3D-CRT/IMRT in patients treated for localized prostate cancer (RTOG 0126). Int J Radiat Oncol Biol Phys. 2014;90(5):1263.CrossRef

35.

Network NCC. Prostate cancer (Version 2.2017). https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed March 1, 2017.

36.

Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26(15):2497–504. doi:10.1200/JCO.2007.14.9021.CrossRefPubMed

37.

Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360(24):2516–27. doi:10.1056/NEJMoa0810095.CrossRefPubMed

38.

Abdenour Nabid NC, André-Guy M, Bahary J-P, Souhami L, Duclos M, Vincent F, Vass S, Bahoric B, Archambault R, Lemaire C. High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: results of a phase III randomized study. J Clin Oncol. 2013;31(suppl 6; abstr 3).

39.

Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, et al. Final report of multicenter Canadian phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73(2):327–33. doi:10.1016/j.ijrobp.2008.04.075.CrossRefPubMed

40.

Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015;33(4):332–9. doi:10.1200/JCO.2014.58.0662.CrossRefPubMed

41.

• Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodriguez MA, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(3):320–7. doi:10.1016/S1470-2045(15)70045-8. This phase III trial demonstrated improved outcomes with longer duration ADT compared to shorter duration ADT with dose-escalated RT. CrossRefPubMed

42.

Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, et al. Effect of long-term hormonal therapy (vs short-term hormonal therapy): a secondary analysis of intermediate-risk prostate cancer patients treated on NRG oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017;97(3):511–5. doi:10.1016/j.ijrobp.2016.11.002.CrossRefPubMed

43.

Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, et al. Duration of androgen deprivation therapy for high-risk prostate cancer: application of randomized trial data in a tertiary referral cancer center. Clin Genitourin Cancer. 2016;14(4):e299–305. doi:10.1016/j.clgc.2015.12.008.CrossRefPubMed

44.

Son CH, Hamstra DA, Feng FY, Liauw SL. High-risk prostate cancer treated with dose-escalated RT: an analysis of hormonal therapy use and duration, and prognostic implications of PSA nadir </=0.2 to select men for short-term hormonal therapy. Am J Clin Oncol. 2014; doi:10.1097/COC.0000000000000161.PubMed

45.

Williams S, Buyyounouski M, Kestin L, Duchesne G, Pickles T. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose. Int J Radiat Oncol Biol Phys. 2011;79(3):724–31. doi:10.1016/j.ijrobp.2009.11.044.CrossRefPubMed

46.

Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys. 2000;48(2):355–67.CrossRefPubMed

47.

Stock RG, Stone NN, Kao J, Iannuzzi C, Unger P. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization. Cancer. 2000;89(8):1829–34.CrossRefPubMed

48.

Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2006;64(2):527–33. doi:10.1016/j.ijrobp.2005.07.981.CrossRefPubMed

49.

Liauw SL, Fricano J, Correa D, Weichselbaum RR, Jani AB. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores. Cancer. 2009;115(8):1784–90. doi:10.1002/cncr.24176.CrossRefPubMed

50.

Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64(6):895–902. doi:10.1016/j.eururo.2013.03.033.CrossRefPubMed

51.

Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69(3):428–35. doi:10.1016/j.eururo.2015.06.046.CrossRefPubMed

52.

Tran PT, Hales RK, Zeng J, Aziz K, Salih T, Gajula RP, et al. Tissue biomarkers for prostate cancer radiation therapy. Curr Mol Med. 2012;12(6):772–87.CrossRefPubMedPubMedCentral

53.

Khor LY, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol. 2007;8(10):912–20. doi:10.1016/S1470-2045(07)70280-2.CrossRefPubMedPubMedCentral

54.

Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, et al. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017; doi:10.1038/pcan.2016.58.PubMedCentral

55.

Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–36. doi:10.1016/j.eururo.2014.07.010.CrossRefPubMed

56.

Valicenti RK, Bae K, Michalski J, Sandler H, Shipley W, Lin A, et al. Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of radiation therapy oncology group 94-06. Int J Radiat Oncol Biol Phys. 2011;79(5):1323–9. doi:10.1016/j.ijrobp.2010.01.009.CrossRefPubMed

57.

Zumsteg ZS, Spratt DE, Pei X, Yamada Y, Kalikstein A, Kuk D, et al. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(4):1012–7. doi:10.1016/j.ijrobp.2012.07.2374.CrossRefPubMed

58.

Feng FY, Blas K, Olson K, Stenmark M, Sandler H, Hamstra DA. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2013;86(1):64–71. doi:10.1016/j.ijrobp.2012.11.024.CrossRefPubMed

59.

D'Amico AV, Chen MH, de Castro M, Loffredo M, Lamb DS, Steigler A, et al. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol. 2012;13(2):189–95. doi:10.1016/S1470-2045(11)70295-9.CrossRefPubMed

60.

Zelefsky MJ, Chou JF, Pei X, Yamada Y, Kollmeier M, Cox B, et al. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: the Memorial Sloan-Kettering Cancer Center experience. Brachytherapy. 2012;11(4):245–9. doi:10.1016/j.brachy.2011.08.003.CrossRefPubMed

61.

• Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2016; doi:10.1016/j.ijrobp.2016.11.026. This randomized trial demonstrated improved biochemical outcomes with brachtherapy boost compared to external beam RT in intermediate and high-risk patients receiving combined ADT/RT.

62.

Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, et al. Clinical outcomes for patients with Gleason score 9-10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis. Eur Urol. 2016; doi:10.1016/j.eururo.2016.06.046.PubMed

63.

Keyes M, Merrick G, Frank SJ, Grimm P, Zelefsky MJ. American Brachytherapy Society task group report: use of androgen deprivation therapy with prostate brachytherapy-a systematic literature review. Brachytherapy. 2017; doi:10.1016/j.brachy.2016.11.017.PubMed

64.

Savdie R, Horvath LG, Benito RP, Rasiah KK, Haynes AM, Chatfield M, et al. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU Int. 2012;109(12):1794–800. doi:10.1111/j.1464-410X.2011.10572.x.CrossRefPubMed

65.

Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25(16):2225–9. doi:10.1200/JCO.2006.09.6495.CrossRefPubMed

66.

Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, et al. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: results of NRG oncology/RTOG study 0621. Cancer. 2017; doi:10.1002/cncr.30620.PubMed

67.

Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016; doi:10.1200/JCO.2016.67.9647.PubMed

68.

Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56. doi:10.1200/JCO.2006.06.2497.CrossRefPubMed

69.

Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359–66. doi:10.1001/jama.2011.1745.CrossRefPubMed

70.

Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ, et al. Androgen deprivation therapy and future Alzheimer’s disease risk. J Clin Oncol. 2016;34(6):566–71. doi:10.1200/JCO.2015.63.6266.CrossRefPubMed

71.

Tsai HT, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, et al. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015;193(6):1956–62. doi:10.1016/j.juro.2014.12.027.CrossRefPubMed

72.

Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. 2012;118(13):3397–406. doi:10.1002/cncr.26623.CrossRefPubMed

73.

Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L. Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism. Eur Urol. 2016;70(1):56–61. doi:10.1016/j.eururo.2015.06.022.CrossRefPubMed

74.

Locke JA, Dal Pra A, Supiot S, Warde P, Bristow RG. Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nat Rev Urol. 2015;12(4):193–204. doi:10.1038/nrurol.2015.50.CrossRefPubMed

Title: The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update
Authors: Greg Kauffmann
Stanley L. Liauw
Publication date: 01-07-2017
Publisher: Springer US
Published in: Current Urology Reports / Issue 7/2017
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-017-0698-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 7/2017

Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary

Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer

Testosterone Therapy on Active Surveillance and Following Definitive Treatment for Prostate Cancer

Therapeutic Value of Standard Versus Extended Pelvic Lymph Node Dissection During Radical Prostatectomy for High-Risk Prostate Cancer

Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies

The Preoperative Assessment and Optimization of Patients Undergoing Major Urological Surgery